Redefining latent tuberculosis

Future Microbiology

Volumn 6, Issue 9, 2011, Pages 1021-1035

  Sridhar, Saranya ^a   Pollock, Katrina ^a   Lalvani, Ajit ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

IFN release assays; immunology; latent tuberculosis; Mycobacterium tuberculosis; public health; tuberculosis control; tuberculosis diagnosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; TUBERCULIN;

BCG VACCINATION; CLINICAL ASSESSMENT; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDEMIOLOGICAL DATA; HEALTH CARE POLICY; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MICROBIAL GENETICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADAPTIVE IMMUNITY; ANIMALS; COMMUNICABLE DISEASE CONTROL; GENOME, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LATENT TUBERCULOSIS; MYCOBACTERIUM; VACCINATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80053536138     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.82     Document Type: Review

References (128)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), 677-686 (1999).
2. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-g assay for the management of tuberculosis. Curr. Opin. Pulm. Med. 11(3), 195-202 (2005). (Pubitemid 40577168)
3. Lalvani A, Pareek M. Interferon g release assays: principles and practice. Enferm. Infecc. Microbiol. Clin. 28(4), 245-252 (2010).
4. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl Acad. Sci. USA 99(6), 3684-3689 (2002). (Pubitemid 34252166)
5. Russell DG. Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5(1), 39-47 (2007). (Pubitemid 44942302)
6. Hingley-Wilson SM, Lougheed KE, Ferguson K, Leiva S, Williams HD. Individual Mycobacterium tuberculosis universal stress protein homologues are dispensable in vitro. Tuberculosis (Edinb.) 90(4), 236-244 (2010).
7. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537-544 (1998). (Pubitemid 28319235)
8. Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J. Infect. Dis. 187(1), 117-123 (2003). (Pubitemid 36034479)
9. Hsu T, Hingley-Wilson SM, Chen B, et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc. Natl Acad. Sci. USA 100(21), 12420-12425 (2003). (Pubitemid 37271575)
10. Abdallah AM, Gey Van Pittius NC, Champion PA, et al. Type VII secretion-mycobacteria show the way. Nat. Rev. Microbiol. 5(11), 883-891 (2007). (Pubitemid 47578389)
11. Champion PA, Stanley SA, Champion MM, Brown EJ, Cox JS. C-terminal signal sequence promotes virulence factor secretion in Mycobacterium tuberculosis. Science 313(5793), 1632-1636 (2006). (Pubitemid 44414036)
12. Van Ingen J, De Zwaan R, Dekhuijzen R, Boeree M, Van Soolingen D. Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical character. J. Bacteriol. 191(18), 5865-5867 (2009).
13. Skjot RL, Oettinger T, Rosenkrands I, et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 68(1), 214-220 (2000). (Pubitemid 30016699)
14. Sutherland I, Svandova E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63(4), 255-268 (1982).
15. Bogen E, Butt EM, Djang AH, Aijian HS. Frequency of tuberculous lesions discovered at autopsy at Los Angeles County General Hospital, 1918-1948. Calif. Med. 73(6), 566-569 (1950).
16. Ktsanes VK, Williams WL, Boudreaux VV. The cumulative risk of tuberculin skin test conversion for five years of hospital employment. Am. J. Pub. Health 76(1), 65-67 (1986). (Pubitemid 16177554)
17. Baussano I, Bugiani M, Carosso A, et al. Risk of tuberculin conversion among healthcare workers and the adoption of preventive measures. Occup. Environ. Med. 64(3), 161-166 (2007). (Pubitemid 46579824)
18. Larsen NM, Biddle CL, Sotir MJ, White N, Parrott P, Blumberg HM. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. Clin. Infect. Dis. 35(7), 796-801 (2002).
19. Jee SH, Golub JE, Jo J, Park IS, Ohrr H, Samet JM. Smoking and risk of tuberculosis incidence, mortality, and recurrence in South Korean men and women. Am. J. Epidemiol. 170(12), 1478-1485 (2009).
20. Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis -a systematic review. BMC Pub. Health 8, 289 (2008).
21. Hwang LY, Grimes CZ, Beasley RP, Graviss EA. Latent tuberculosis infections in hard-to-reach drug using population-detection, prevention and control. Tuberculosis (Edinb.) 89(Suppl. 1) S41-S45 (2009).
22. Burki T. Tackling tuberculosis in Londons homeless population. Lancet 376(9758), 2055-2056 (2010).
23. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358(9294), 1687-1693 (2001). (Pubitemid 33124328)
24. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191(2), 150-158 (2005). (Pubitemid 40096371)
25. Feingold AO. Cost effectiveness of screening for tuberculosis in a general medical clinic. Pub. Health Rep. 90(6), 544-547 (1975).
26. Pamra SP, Mathur GP. Effects of chemoprophylaxis on minimal pulmonary tuberculosis lesions of doubtful activity. Bull. World Health Organ. 45(5), 593-602 (1971).
27. Grzybowski S, Ashley MJ, Mckinnon NE, Pinkus G, Philipps R, Brown A. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Can. Med. Assoc. J. 101(9), 81-86 (1969).
28. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest 73(1), 44-48 (1978). (Pubitemid 8271998)
29. Eisenberg RL, Pollock NR. Low yield of chest radiography in a large tuberculosis screening program. Radiology 256(3), 998-1004 (2010).
30. Cooper AM. Cell-mediated immune responses in tuberculosis. Ann. Rev. Immunol. 27, 393-422 (2009).
31. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 173(7), 803-810 (2006).
32. Scriba TJ, Kalsdorf B, Abrahams DA, et al. Distinct, specific IL-17-and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J. Immunol. 180(3), 1962-1970 (2008).
33. Montamat-Sicotte DJ, Millington KA, Willcox CR, et al. A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection. J. Clin. Invest. 121(6), 2493-2503 (2011).
34. Narain R, Nair SS, Rao GR, Chandrasekhar P, Lal P. Enhancing of tuberculin allergy by previous tuberculin testing. Bull. World Health Organ. 34(4), 623-638 (1966).
35. Narain R, Bagga AS, Naganna K, Mayurnath S. Influence of isoniazid on naturally acquired tuberculin allergy and on induction of allergy by BCG vaccination. Bull. World Health Organ. 43(1), 53-64 (1970).
36. Magnus K. Epidemiological basis of tuberculosis eradication. 6. Tuberculin sensitivity after human and bovine infection. Bull. World Health Organ. 36(5), 719-731 (1967).
37. Joncas JH, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children. Can. Med. Assoc. J. 113(2), 127-128 (1975).
38. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149(3), 177-184 (2008).
39. Swaim LE, Connolly LE, Volkman HE, Humbert O, Born DE, Ramakrishnan L. Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. Infect. Immun. 74(11), 6108-6117 (2006). (Pubitemid 44657389)
40. Capuano SV 3rd, Croix DA, Pawar S, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71(10), 5831-5844 (2003). (Pubitemid 37205637)
41. Ghon A. The Primary Lung Focus of Tuberculosis in Children (English). Churchill, London, UK (1916).
42. Ulrichs T, Kosmiadi GA, Jorg S, et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J. Infect. Dis. 192(1), 89-97 (2005). (Pubitemid 40863861)
43. Kim M J, Wainwright H C, Locketz M, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2(7), 258-274 (2010).
44. Flynn JL, Chan J. Whats good for the host is good for the bug. Trends Microbiol. 13(3), 98-102 (2005).
45. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356(9248), 2133-2138 (2000).
46. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7(12), 845-855 (2009).
47. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull. Int. Union Tuberc. 50(1), 90-106 (1975).
48. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect. Dis. 8(6), 359-368 (2008).
49. Cobat A, Gallant CJ, Simkin L, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 206(12), 2583-2591 (2009).
50. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am. J. Respir. Crit. Care Med. 174(3), 349-355 (2006). (Pubitemid 44156616)
51. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 174(7), 831-839 (2006). (Pubitemid 44511666)
52. Nardell EA, Wallis RS. Here today-gone tomorrow: the case for transient acute tuberculosis infection. Am. J. Respir. Crit. Care Med. 174(7), 734-735 (2006). (Pubitemid 44511653)
53. Hussain R, Talat N, Shahid F, Dawood G. Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development. Clin. Vaccine Immunol. 14(12), 1578-1586 (2007).
54. Millington KA, Gooding S, Hinks TS, et al. Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis. J. Infect. Dis. 202(11), 1685-1689 (2010).
55. Cockle PJ, Gordon SV, Lalvani A, Buddle BM, Hewinson RG, Vordermeier HM. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect. Immun. 70(12), 6996-7003 (2002). (Pubitemid 35387935)
56. Chee CB, Khinmar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-g responses to Mycobacterium tuberculosis-specific antigens. Eur. Respir. J. 36(2), 355-361 (2010).
57. Chee CB, Khinmar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am. J. Respir. Crit. Care Med. 175(3), 282-287 (2007). (Pubitemid 46203133)
58. Hill PC, Brookes RH, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med. 4(6), e192 (2007).
59. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104 (2001).
60. Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77(10), 4631-4642 (2009).
61. Day CL, Mkhwanazi N, Reddy S, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J. Infect. Dis. 197(7), 990-999 (2008). (Pubitemid 351590027)
62. Wilkinson KA, Seldon R, Meintjes G, et al. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 180(7), 674-683 (2009).
63. Sutherland JS, Young JM, Peterson, KL, et al. Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J. Immunol. 184(11), 6537-6544 (2010).
64. Hinks TS, Dosanjh DP, Innes JA, et al. Frequencies of region of difference 1 antigen-specific but not purified protein derivative-specific g interferon-secreting T cells correlate with the presence of tuberculosis disease but do not distinguish recent from remote latent infections. Infect. Immun. 77(12), 5486-5495 (2009).
65. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-g release assay in HIV-1-infected individuals. Clin. Infect. Dis. 48(7), 954-962 (2009).
66. Del Corral H, Paris SC, Marin ND, et al. IFNg response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS ONE 4(12), e8257 (2009).
67. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-g assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 177(10), 1164-1170 (2008). (Pubitemid 351717577)
68. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood IGRA for developing active TB -An update. Am. J. Respir. Crit. Care Med. (2010).
69. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40(2), 704-706 (2002). (Pubitemid 34130912)
70. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 3(1), e1379 (2008).
71. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur. Respir. J. 35(6), 1346-1353 (2010).
72. Chang KC, Leung CC. Systematic review of interferon-g release assays in tuberculosis: focus on likelihood ratios. Thorax 65(3), 271-276.
73. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-g release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 5(5), e10508 (2010).
74. Mahomed H, Hughes EJ, Hawkridge T, et al. Comparison of mantoux skin test with three generations of a whole blood IFN-g assay for tuberculosis infection. Int. J. Tuberc. Lung Dis. 10(3), 310-316 (2006).
75. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int. J. Tuberc. Lung Dis. 14(7), 819-827 (2010).
76. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-g biomarker in children with tuberculosis contact. Ann. Intern. Med. 149(11), 777-787 (2008).
77. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. (2010).
78. Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber. Lung Dis. 79(4), 243-250 (1999). (Pubitemid 29446012)
79. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9), 698-702 (1994). (Pubitemid 24061706)
80. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517), 1173-1180 (2006).
81. Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy. A methodological and statistical reappraisal. JAMA 249(17), 2362-2369 (1983). (Pubitemid 13137041)
82. Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 60(4), 225-231 (1979). (Pubitemid 10167306)
83. Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366(9495), 1443-1451 (2005). (Pubitemid 41483810)
84. Eisenhut M, Paranjothy S, Abubakar I, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by g interferon release assay. Vaccine 27(44), 6116-6120 (2009).
85. Eriksen J, Chow JY, Mellis V, et al. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold? Thorax 65(12), 1067-1071 (2010).
86. Hess J, Kaufmann SH. Development of novel tuberculosis vaccines. C. R. Acad. Sci. III 322, 953-958 (1999).
87. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res. Notes 2, 19 (2009).
88. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, Ravn P. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect. 9(7), 806-812 (2007). (Pubitemid 46901043)
89. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 32(6), 1607-1615 (2008).
90. Abramo C, Meijgaarden KE, Garcia D, et al. Monokine induced by interferon g and IFN-g response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes Infect. 8(1), 45-51 (2006). (Pubitemid 43139291)
91. Liu XQ, Dosanjh D, Varia H, et al. Evaluation of T-cell responses to novel RD1-and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection. Infect. Immun. 72(5), 2574-2581 (2004). (Pubitemid 38542383)
92. Dosanjh DP, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann. Intern. Med. 148(5), 325-336 (2008). (Pubitemid 351665463)
93. Harada N, Higuchi K, Yoshiyama T, et al. Comparison of the sensitivity and specificity of two whole blood interferon-g assays for M. tuberculosis infection. J. Infect. 56(5), 348-353 (2008).
94. Millington KA, Innes JA, Hackforth S, et al. Dynamic relationship between IFN-g and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J. Immunol. 178(8), 5217-5226 (2007). (Pubitemid 46595306)
95. Sester U, Fousse M, Dirks J, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS ONE 6(3), e17813 (2011).
96. Caccamo N, Guggino G, Meraviglia S, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 4(5), e5528 (2009).
97. Casey R, Blumenkrantz D, Millington K, et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS ONE 5(12), e15619 (2010).
98. Harari A, Rozot V, Enders FB, et al. Dominant TNF-a(+) Mycobacterium tuberculosis-specific CD4(+) T cell responses discriminate between latent infection and active disease. Nat. Med. 17(3), 372-376 (2011).
99. Day CL, Abrahams DA, Lerumo L, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187(5), 2222-2232 (2011).
100. Wu B, Huang C, Kato-Maeda M, et al. Messenger RNA expression of IL-8, FOXP3, and IL-12b differentiates latent tuberculosis infection from disease. J. Immunol. 178(6), 3688-3694 (2007). (Pubitemid 46417636)
101. Hougardy JM, Schepers K, Place S, et al. Heparin-binding-hemagglutinin- induced IFN-g release as a diagnostic tool for latent tuberculosis. PLoS ONE 2(10), e926 (2007).
102. Leyten EM, Lin MY, Franken KL, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 8(8), 2052-2060 (2006). (Pubitemid 44311602)
103. Schuck SD, Mueller H, Kunitz F, et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS ONE 4(5), e5590 (2009).
104. Gideon HP, Wilkinson KA, Rustad TR, et al. Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines. PLoS Pathog. 6(12), e1001237 (2010).
105. Govender L, Abel B, Hughes EJ, et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 29(1), 51-57 (2010).
106. Berry MP, Graham CM, Mcnab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
107. Mistry R, Cliff JM, Clayton CL, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J. Infect. Dis. 195(3), 357-365 (2007). (Pubitemid 46146113)
108. Lalvani A, Sridhar S. BCG vaccination: 90 years on and still so much to learn. Thorax 65(12), 1036-1038 (2010).
109. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am. J. Respir. Crit. Care Med. (2010).
110. Ronan EO, Lee LN, Beverley PC, Tchilian EZ. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 4(12), e8235 (2009).
111. Forbes EK, Sander C, Ronan EO, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181(7), 4955-4964 (2008).
112. Herrera MT, Torres M, Nevels D, et al. Compartmentalized bronchoalveolar IFN-g and IL-12 response in human pulmonary tuberculosis. Tuberculosis (Edinb.) 89(1), 38-47 (2009).
113. Carranza C, Juarez E, Torres M, Ellner JJ, Sada E, Schwander SK. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. Am. J. Respir. Crit. Care Med. 173(2), 238-245 (2006). (Pubitemid 43187898)
114. Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am. J. Respir. Crit. Care Med. 180(12), 1262-1270 (2009).
115. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am. J. Respir. Crit. Care Med. 183(6), 696-707 (2011).
116. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect. Dis. 11(6), 435-444 (2011).
117. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106(33), 13980-13985 (2009).
118. Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J. Infect. Dis. doi: 10.1093/infdis/jir449 (2011) (Epub ahead of print).
119. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 377(9777), 1588-1598 (2011).
120. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-g release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J. Acquir. Immu. Defic. Syndr. 56(3), 230-238 (2011).
121. Department of Health: Immunisation Against Infectious Disease -The Green Book -2006 Updated Edition. Salisbury D, Ramsay M, Noakes K (Eds). The Stationery Office under licence from the Department of Health, London, UK (2006).
122. No authors listed. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, 1999. Am. J. Respir. Crit. Care Med. 161(4 Pt 1), 1376-1395 (2000).
123. Diel R, Goletti D, Ferrara G, et al. Interferon-g release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur. Respir. J. 37(1), 88-99 (2010).
124. Millington KA, Fortune SM, Low J, et al. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 108(14), 5730-5735 (2011).
125. World Health Organisation. Global tuberculosis control: WHO report 2010 www.who.int/tb/publications/global-report/2010/en/index.html
126. Nabarro LE, Connell DW, George PM. Re-defining the clinical syndrome of TB uveitis with modern diagnostic modalities www.ers-education.org/pages/ default. aspx?id=2320&idBrowse=80659
127. NICE. Clinical Guidelines 117. (2011) www.nice.org.uk/guidance/index. jsp?action=byID&o=13422
128. Tuberculin PPD RT 23 SSI www.ssi.dk/English/Vaccines/ Tuberculin%20PPD%20RT%2023%20SSI. Aspx